Examkin

Question

Difficulty: MediumRheumatology and Immunology

A 28-year-old man with a history of HLA-B27 positivity is diagnosed with active ankylosing spondylitis. He presents with worsening inflammatory back pain and morning stiffness. Arrange the following therapeutic steps in the standard chronological sequence of escalation for the management of his condition, assuming an inadequate response or disease progression at each preceding stage.

  1. 1Continuous therapy with a nonsteroidal anti-inflammatory drug (e.g., naproxen) alongside physical therapy
  2. 2Initiation of a tumor necrosis factor (TNF) inhibitor (e.g., etanercept)
  3. 3Switching to an interleukin-17 (IL-17) inhibitor (e.g., secukinumab)
  4. 4Surgical evaluation for corrective spinal osteotomy or total joint arthroplasty

Answer

The correct sequence of therapy escalation for ankylosing spondylitis begins with continuous NSAIDs, followed by a TNF inhibitor, then an IL-17 inhibitor if the TNF inhibitor fails, and finally surgical intervention for irreversible structural damage.
The established algorithm for axial spondyloarthritis (ankylosing spondylitis) mandates starting with continuous NSAIDs. If disease activity remains high, biological therapy is initiated, typically starting with a TNF inhibitor. If this fails, transitioning to a different biologic class (such as an IL-17 inhibitor) is indicated. Finally, if all medical management fails to prevent severe structural damage leading to profound functional impairment, surgical options like spinal osteotomy are explored.

Step-by-Step Solution

1
Identify the first-line treatment for active ankylosing spondylitis.
Continuous NSAIDs and physical therapy are selected.
Unlike rheumatoid arthritis where conventional DMARDs are first-line, axial spondyloarthritis responds best initially to continuous NSAID therapy.
2
Determine the next step for a patient who fails continuous NSAID therapy.
A biologic DMARD, specifically a TNF inhibitor, is added.
TNF inhibitors have robust efficacy in reducing axial inflammation and are the preferred first-line biologics for this condition.
3
Determine the next pharmacologic step if a TNF inhibitor fails.
Therapy is switched to an IL-17 inhibitor.
When a first biologic fails, guidelines recommend switching classes. IL-17 inhibitors (e.g., secukinumab, ixekizumab) are highly effective alternative options for axial disease.
4
Identify the end-stage management for refractory structural complications.
Surgical evaluation is considered.
Medical therapy cannot reverse fixed bony ankylosis; severe functional impairment from structural damage may require osteotomy or arthroplasty.

Key Concept

The stepwise pharmacological and procedural escalation in ankylosing spondylitis progresses from continuous NSAIDs to TNF inhibitors, followed by IL-17 inhibitors for non-responders, and ultimately surgery for severe structural deformities.
Rate this question

Topics

Rheumatology and Immunology

More questions from this topic